

# aap Implantate AG

Financial results

Loqteq on track and pipeline progressing

aap's initial 2014 outlook underlines its aim to grow profits faster than sales. The key driver remains Loqteq. Clinical data from the ongoing post-marketing study and a decision on a US partner are both anticipated during 2014. The pipeline, including silver-coated plates and resorbable magnesium implants, continues to progress as planned. Our forecasts are unchanged and our valuation remains €3.3/share based on a DCF.

Year end	Revenue (€m)	PBT* (€m)	EPS* (€)	DPS (€)	P/E (x)	Yield (%)
12/11	29.2	2.7	0.08	0.0	25.0	N/A
12/12	36.4	4.9	0.14	0.0	14.3	N/A
12/13e	40.1	6.0	0.17	0.0	11.8	N/A
12/14e	44.5	6.7	0.20	0.0	10.0	N/A

Note: \*PBT and EPS are normalised, excluding intangible amortisation, exceptional items and share-based payments.

## Loqteq on track; data and US decision in H114

Loqteq sales grew +83% to €1.1m in Q3 and +182% to €3.1m ytd. Data from the ongoing post-marketing study are expected during Q114, and a decision on US partnering is anticipated during 2014. aap already has a two-year, non-exclusive agreement with an undisclosed partner, which expires at the end of 2014.

## Promising pipeline potential

Beyond Loqteq, aap is working on a number of pipeline opportunities, including silver-coated trauma plates to reduce infection and biodegradable magnesium implants for small bone fractures. The ongoing initial preclinical trials with the silver-coated products are progressing positively, with data expected in Q114 before moving to the proof-of-concept clinical phase. The JV with eontec Co for resorbable magnesium implants is progressing as planned.

## Aiming to grow profits faster than sales

aap is on track to deliver on its reiterated 2013 guidance of 10% sales growth to around €40m and 15% EBITDA growth to around €7m. It has also provided a first outlook for 2014 and remains focused on growing profits faster than sales. Sales growth of around 10% and EBITDA growth of around 15% are anticipated in 2014, both of which represent minimum targets. Based on 2013 guidance, this implies sales of €44m and EBITDA of €8m, both in line with our unchanged forecasts.

## Valuation: €100m based on DCF

Our €100m or €3.3/share DCF valuation is unchanged. We forecast 10% 2012-15 revenue CAGR and a doubling of current sales to around €80m by 2020, driven by Loqteq. In addition we assume EBITDA margins can expand around 200 basis points over the next two to three years. In the longer term we expect operating margins to reach around 25% from 14% today.

Healthcare equipment &amp; services

27 November 2013

**Price** €2.00

**Market cap** €61m

Net cash (€m) as at end September 2013 3.0

Shares in issue 30.7m

Free float 34%

Code AAQ

Primary exchange Xetra

Secondary exchange N/A

### Share price performance



% 1m 3m 12m

Abs 36.4 47.4 45.2

Rel (local) 31.9 33.8 14.0

52-week high/low €2.3 €1.2

### Business description

aap Implantate is a German medical technology company focused on developing, manufacturing and selling products for bone fractures. These include the recently launched Loqteq trauma plating system, in addition to bone cements.

### Next events

Loqteq post-marketing study data Q114

Loqteq US partnership decision H114

### Analysts

Dr Philippa Gardner +44 (0)20 3681 2521

Dr Mick Cooper +44 (0)20 3077 5734

Robin Davison +44 (0)20 3077 5737

[healthcare@edisongroup.com](mailto:healthcare@edisongroup.com)
[Edison profile page](#)

## Loqteq on track; data and US decision in H114e

The key growth driver for aap in the near and medium term remains Loqteq, aap's internally developed and recently launched trauma plating system. Data from the ongoing post-marketing study anticipated in Q114 could provide the first clinical evidence of Loqteq's potential cold-welding advantage. Cold-welding causes problems during explantation (plate removal). In the US, a two-year beta launch with an undisclosed, non-exclusive partner is underway to understand Loqteq's acceptance. Management reported that initial feedback is encouraging, with Loqteq being well received by surgeons. The next step is to determine the optimal partnering strategy for this key market. A number of potential options are being considered.

## Pipeline beyond Loqteq

aap continues to progress its pipeline of innovative medtech products. These include:

- **Silver-coated trauma products:** aap is working to develop silver-coated trauma implants in order to improve infection prevention. Current trauma implants are not coated and hence the application of certain coatings, such as silver, or controlled release of an antibiotic could prevent infections and improve healing. Animal trials are progressing positively, with data anticipated in Q114. First market entry could come from 2015.
- **Resorbable magnesium implants:** In March 2013 aap and eontec Co, a Chinese magnesium specialist, agreed to form a 50:50 JV for the development of resorbable magnesium implants. Such implants could be used in trauma applications, particularly for small implants in, for example, hands and feet, and would remove the need for later explantation of the implant. eontec develops and produces magnesium products for the electronics industry. Hence the JV combines aap's trauma expertise with eontec's magnesium knowledge. Human clinical trials are ongoing, with costs shared equally.

## Temporary slowdowns should reverse in Q413

There has already been a recovery in bone cements in Q3, following a temporary slowdown earlier in the year; during H113 bone cements revenues had declined by €3.0m, with only a €0.4m decrease in Q313. New customers are coming on board and management expects strong sales in Q413, with orders already ahead of Q412. In addition, there was a one-off slight seasonal fluctuation in medical aesthetic products, but the overall business remains intact.

## No changes to forecasts; valuation remains €3.3/share based on DCF

We value aap at €100m or €3.3/share based on a DCF valuation assuming a WACC of 12.5%, terminal growth of 2.0% and a long-term tax rate of 25%. Our key revenue growth assumptions are shown in Exhibit 1. We expect around a 200 basis point improvement in product gross margin owing to the changing product mix, and anticipate some cost efficiencies in the future, driving operating margin expansion to c 16% by 2015 from 14% in 2012. In the longer term as Loqteq grows, we believe operating margins could reach around 25% from 14% currently.

If we assume Loqteq peaks at sales of €5m, and that long-term operating margins remain at 16%, our DCF valuation is €44m or €1.4/share, providing downside protection.

### Exhibit 1: Base case revenue assumptions

€m	2011	2012	2013e	2014e	2015e
Biomaterials	22.4	28.6	30.0	28.4	28.9
Trauma & Orthopaedics (ex-Loqteq)	6.4	5.8	5.0	5.6	6.1
Loqteq	0.4	2.1	5.0	10.5	14.0

Source: aap, Edison Investment Research

**Exhibit 2: Financial summary**

	€000s	2008	2009	2010	2011	2012	2013e	2014e	2015e
December		IFRS	IFRS	IFRS	IFRS	IFRS	IFRS	IFRS	IFRS
<b>PROFIT &amp; LOSS</b>									
Revenue		31,884	33,101	28,440	29,205	36,414	40,053	44,523	48,978
Total Output		36,476	34,788	32,560	33,003	39,337	42,806	47,210	51,653
Cost of Sales		(9,233)	(7,411)	(9,535)	(8,078)	(10,776)	(11,706)	(13,842)	(15,110)
Gross Profit		22,651	25,690	18,905	21,127	25,638	28,347	30,680	33,868
EBITDA		3,713	6,563	3,448	4,126	6,106	7,300	8,107	9,260
Operating Profit (before amort. and except.)		2,300	5,313	2,406	3,072	5,034	6,125	6,763	7,746
Intangible Amortisation		(6,935)	(1,719)	(1,687)	(1,907)	(2,837)	(2,095)	(2,136)	(2,240)
Exceptionals		0	0	0	0	1,015	0	0	0
Other		(6)	(306)	(174)	(220)	(316)	(300)	0	0
Operating Profit		(4,641)	3,288	545	945	2,896	3,730	4,628	5,506
Net Interest		(917)	(534)	(359)	(327)	(176)	(129)	(76)	(35)
Profit Before Tax (norm)		1,383	4,779	2,047	2,745	4,858	5,996	6,688	7,712
Profit Before Tax (FRS 3)		(5,558)	2,754	186	618	2,720	3,601	4,552	5,472
Tax		324	(816)	(135)	(223)	(310)	(500)	(600)	(675)
Profit After Tax (norm)		1,701	3,657	1,738	2,302	4,232	5,196	6,088	7,037
Profit After Tax (FRS 3)		(5,234)	1,938	51	395	2,410	3,101	3,952	4,797
Average Number of Shares Outstanding (m)		26.2	27.6	27.8	29.6	30.7	30.7	30.7	30.7
EPS - normalised (€)		0.07	0.13	0.06	0.08	0.14	0.17	0.20	0.23
EPS - normalised and fully diluted (€)		6.62	0.13	0.06	0.08	0.14	0.17	0.20	0.23
EPS - (IFRS) (€)		(0.20)	0.07	0.00	0.01	0.08	0.10	0.13	0.16
Dividend per share (p)		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross Margin (%)*		71.0	74.1	65.4	72.3	68.1	68.1	68.3	68.8
EBITDA Margin (%)		11.6	19.8	12.1	14.1	16.8	18.2	18.2	18.9
Operating Margin (before GW and except.) (%)		7.2	16.1	8.5	10.5	13.8	15.3	15.2	15.8
<b>BALANCE SHEET</b>									
Fixed Assets		44,493	41,066	42,597	43,675	44,921	45,797	48,306	50,588
Intangible Assets		34,506	35,528	37,000	38,248	39,403	36,549	37,063	37,430
Tangible Assets		7,309	5,055	5,200	5,071	5,107	7,337	9,333	11,248
Investments		2,678	483	397	356	411	1,911	1,911	1,911
Current Assets		22,537	21,589	21,035	22,476	23,669	24,085	25,922	28,824
Stocks		13,714	11,538	12,688	13,991	13,943	12,791	14,411	14,870
Debtors		6,795	6,007	6,204	5,508	4,226	6,487	6,099	6,709
Cash		96	2,406	909	2,152	3,698	3,005	3,610	5,442
Other		1,932	1,638	1,234	825	1,802	1,802	1,802	1,802
Current Liabilities		(16,334)	(13,596)	(14,986)	(15,126)	(13,018)	(9,139)	(9,446)	(9,755)
Creditors		(8,900)	(7,912)	(9,485)	(9,647)	(8,521)	(8,123)	(8,430)	(8,739)
Short term borrowings		(7,434)	(5,684)	(5,501)	(5,479)	(4,497)	(1,016)	(1,016)	(1,016)
Long Term Liabilities		(9,393)	(4,344)	(3,794)	(2,675)	(4,706)	(6,567)	(6,447)	(6,318)
Long term borrowings		(3,008)	(1,836)	(1,163)	(74)	(2,019)	(4,000)	(4,000)	(4,000)
Other long term liabilities		(6,385)	(2,508)	(2,631)	(2,601)	(2,687)	(2,567)	(2,447)	(2,318)
Net Assets		41,303	44,715	44,852	48,350	50,866	54,175	58,335	63,340
<b>CASH FLOW</b>									
Operating Cash Flow		544	4,761	2,654	3,213	7,088	6,164	7,364	8,679
Net Interest		0	0	0	0	0	(129)	(76)	(35)
Tax		0	0	0	0	0	(453)	(575)	(656)
Capex		(2,459)	(645)	(1,191)	(928)	(1,205)	(3,405)	(3,339)	(3,428)
Acquisitions/disposals		10	5,001	961	138	261	3,000	0	0
Financing		2,763	1,267	45	3,039	(101)	0	0	0
Dividends		0	0	0	(34)	0	0	0	0
Net Cash Flow		858	10,384	2,469	5,428	6,043	5,178	3,374	4,560
Opening net debt/(cash)		9,101	10,346	5,114	5,755	3,401	2,818	2,011	1,406
HP finance leases initiated		0	0	0	0	0	0	0	0
Other**		(2,103)	(5,152)	(3,110)	(3,074)	(5,460)	(4,371)	(2,769)	(2,727)
Closing net debt/(cash)		10,346	5,114	5,755	3,401	2,818	2,011	1,406	(426)

Source: aap accounts, Edison Investment Research. Note: Total output consists of revenues, capitalised development costs and inventory changes. aap's expenses are classified according to nature (material, personnel and other) rather than by function (R&D, sales and marketing etc), hence cost of sales refers to material costs. \*Gross margin refers to underlying product gross margins, based on product sales and excluding licensing income. \*\*Other in the cash flow includes capitalised development costs.

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Services Authority ([www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584](http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584)). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is not regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. [www.edisongroup.com](http://www.edisongroup.com)

#### DISCLAIMER

Copyright 2013 Edison Investment Research Limited. All rights reserved. This report has been commissioned by aap Implantate AG and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is not registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2013. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.